Accelerating Commercialization Cost Saving Health Technologies Report

7/31/2019 Accelerating Commercialization Cost Saving Health Technologies Report

1/25

Acclratng Cmmrcalzatn f

Cst-Savng Halth TchnlgsMAy 2012


2/25

ii

About the contributors

t California HealthCare Foundation wk a a

aaly flfll pm f ala f

all calfa. t Fda pp da ad

va a mpv qaly, a ffy,

ad lw f a.

Booz Allen Hamilton a a ff f

agy ad lgy lg f aly a

y. tday, fm pvd v pmaly

us gvm df, llg, ad vl

mak, ad maj pa, , ad

-f-pf gaa. b All ff l

dp fal kwldg pag agy ad

gaa, gg ad pa, lgy,

ad aalyw m w pald

xp l m ad dma aa

lp lv g plm. hal lad

ad pa b All lp m

ady f wa x.

t Robert Wood Johnson Foundation (RWJF)

f pg al ad ala

fag y. A a lag plapy

dvd xlvly mpvg al ad

ala f all Ama, Fda wk

w a dv gp f gaa ad dvdal

dfy l ad av mpv,

magfl, ad mly ag. Pj

rWJF P Pfl a f-d ad lk

yd val kg xpl l a

g dg f al ad ala.

t von Liebig Center for Entrepreneurism and

Technology Advancement a uc sa Dg Ja

sl f egg ddad alag

ala f uvy lg f

y. tg a ma f ga f pf

f p, mg, ad pal

da, v Lg c gd faly

ad vy v g lgy

mmala p.

t w ak D. hy cg, D f Gawd c f cpa iva a

uvy f calfa a bkly, ad Ja J, fd f iv, f pv pm

lla f t op iva Mdl ad nw Mdl f ealy sag capal pd f p.

t al ak Aa Apdaa, rl oa, PD, ad hal DLg f pp f

llaav ff.


3/25

1

contents

id 2

oppy: t hal iva impav 4

nw bd f hal tlgy 4

t rl f uvy ra 5

t callg f cmmalg ealy-sag hal tlg 6

Dffl f cmmala 6

Appa bdgg Gap 8

htAP ad Pf-f-cp sagy 11

t Wllam J. v Lg c 11

A uq Pgam 12

htAP W 15

Lkg Aad 18

nx sp f htAP W 18

ealy ig ad cda 19

ed 21


4/25

2

1introDuction

i Jaay 2012, The Scientist, a maga vg

a ad lgy lf , ld

a pk- lgap mp w ll p

vy a p va f 2011.1 t

dv, kw a LucAs (Ll ulawd fld cll

mg Aay plafm ad sadw magg),

wa dvlpd y a pf f lal gg

ad gg a uvy f calfa

a L Agl (ucLA) a a way pp da

dag -p ad m g.

D. Aydga oa v ld l a

$10 maal ad a pal pla

advad mpy m fld. t

dv xmplf a w wav f al lgy

a p ad a a dvlpg

wldwd. t w lg a adva fma ad mma lg

mpv ala a, a wll a ffy

ad affdaly. ulmaly, lg ld

play a l ly mpvg a g

dvlpg wld, al lpg add

m al allg f agg, y, ad

da ud sa.

Y dp m pal f v

a LucAsad gwg mpa f

v a f vav lgaadm a fa gfa dl

mmalg vy-gad v. t

a ag fm dffly aag k apal

a lak f xp dd flly dvlp

ad mak a w v. t l a may

pmg w lg v mak a

fm laay mak.

Faly, a m f pl- ad pva-

lad a wkg dg gap w

vy a ad dy g a vay

f appa, ldg mpa vg, p

va pap, va allg,

ad vy gap fdg pgam. ba

ag a ll lavly w,

akld xpm w a vay

f q, a agg a pf ag

f mmala p ad pg

val llaa w mp.

i 2011, Wllam J. v Lg c f

epm ad tlgy Advam a

uc sa Dg, pap w calfa

halca Fda, r Wd J

Fda, ad b All haml, lad agal av alld s calfa hal

tlgy Ala Pgam (htAP). t pgam

wa ad pvd a fm v

ad a calfa w

fdg ad mg mmal

lg a d ala ad xpad

a f dvd. htAP p a

q appa f addg mmala

allg, a m a gal mdl f

a lgy ala w pf f f

ppg -avg al lg a

pf f p (Poc) ag f dvlpm.

i fall 2011, htAP f am f ,

ldg D. oa a gp, v p

$100,000 a adva lg

wad mmala. A pa f a p,

awad a w gagd a ya-lg pap

w v Lg c a ld


5/25

3

mg ad fdg dma Poc. ba

addal dvlpm wll lkly qd f

pd a aally m mak, fll mpa

f htAP av wll maal f m

m. Wa alady la, wv, a v

a LucAs w ad a a f vvg

mmala p, ak htAP. t

mpvd dd ma a pa ad gl a

m lkly al f f lg a

a a a g-qaly a a a lw .

t p glg pp f alag

mmala f -avg al lgad xpl w htAP p a ampg

gv vav lg a a f makg

a fl a makpla.

s 2 d mpav f al

va ad d a mgg d f

lw- al lg. s 3 glg

val f allg aad w aly-ag

lgy mmala ad l m

appa f dgg gap w vy

a ad dy. s 4 a y f

htAP ad f ld pj.

t fal f p d wa

l aad f htAP awad wl ffg

da f gvm, aadm, ad

mmal akld ad g gad

fm htAP xp fa.

Photo 1. LUCAS Holographic Microscope

Credit: Holomic, LLC

Common Commercialization Terms FoundIn This Report

Technology Acceleratora pgam a

pvd fdg, v, ad pp

a ad p w

gal f alag dvlpm ad

mmala f aly-ag lg.

Proof-of-Concept (POC)a p dgd

dm mak faly f a v

y dfg al pfma aga

mak d.

Angel Capitalk apal ppld y

dvdal v, gally f

qy a-p ad aly ag mpa.

Agl vm a f ag f

$100,000$500,000.

Venture Capitalk apal ppld y a v

apal fd, a yp f fm w maag ad

v dply apal xag f qy

g-gw pva mpa. V apal

vm a f x f $2 mll.

Stages of Development

Seed/Start-Upmpay a a p

pd d dvlpm, lkly

flly paal.

Early Stagempay a a pd

v g pl pd. t

pd may mmally avalal ad

gag v.

Impact Investingmakg vm w

f ag pv al mpa yd

a faal .

Asymmetric Risk Profilea mala w

pal k ad wad f a gv vm.

Incubatora pgam gaa a

pvd p w v ad dgd ala fl

dvlpm f w mpa.

Crowdfundinga appa f ag k

apal y aag a wd f v,

a f wm mak a mall vm

llvly add apal qm.


6/25

Alag cmmala f c-savg hal tlg 4

2oPPortunitY:the heALth innoVAtion iMPerAtiVe

A us spm c d

aly f Affdal ca A, ad

Ama ga p f a pdal l,

aly all plal ad lad ag

g: t d f gw al pdg

aal, ad fal lw a gw p

a a k f m am.

F m a a dad, al pdg a

ly pad g dm pd

(GDP) ad wag gw.2 t c f Mda

& Mdad sv (cMs) pj a aal

al xpd wll a aly 20 p f

GDP y d f dad. Dg pd,

gvm a f pdg ld a

50 p, ad pal -f-pk may

a y a m a 40 p.3

Ladg ply v, a cmmwal

Fd ad bkg i, gg a lwg

pdg ad afmg al ym wll

q gfa va a, paym,

a dlvy, ad pa mpwm.4,5 M

al lv a fma l ad

lgy a ky f afma. cly mdal

lg ad lad ag md

av mad dv 50 p m

f pdg gw.6

hwv, al fmalg (al it), a l al

d, a dd fdaal f alg

ay fm.7 F, m g

lad av gd a w al ad mdal

lg a al play a ky l alg

afma.8

Nw Brd f Halth Tchnlgbw w xm f g- mdal

lg ad ffy-dvg al it, a w

ga f -avg al lg

mgg. t w va a appaga vg p a ala,

lf , fma lgy, ad

lmma d. (s Fg 1

fllwg pag.) A w LucAs, y a f

plafm-ad v applal mlpl

d ad w pal val ud

sa, a wll a dvlpg wld.

t a ad p dvlpg

-avg al lg a apag

w paym a a fav aly dag

ad pv, a a apalg wafl,

vlm- ad y-ad mm mdl.

iad f g-, aw- mdal lg

ad al fma ym dgd f

llg, v a lvagg lgal

advam, a ml, lw-pw

, wl wk, ad ld mpg,

afm dlvy p ad allg adal

.

if va a fl gg

v mak, -avg al lga appld lp mpv pv, dag,

ad am f da. A am m, y

wll al d f a away fm ly

a vm, y pmg m ff

f lal .


7/25

5

Th Rl f Unvrst RsarchDp gfa pp f dvlpm

f dpv pd ad v aldy, lag ala, lf , ad

lgy mpa ggl kp pa w

dmad f va. t allg

f dvlpg w lg may lag fm

m fm val . Fm ppv

f ladp ad v, dg w

ffg mak pfma dffl pd.

A a l, xv ad ald f y

away fm k a ld dm aal

xg v am. i add, a majy f

mply lag mpa lak a pal

md a y v paal l a

wad pfma a a k.9

cpa a ad dvlpm pa av al

dg gfa ag la 40 ya. t

adal a ad dvlpm (r&D) mdl

w mpa vd al a ad

fd fm a v yl f pfal va

ad vma adly dd, ag lag

mpa agly ly xal llaa

f dvlpg ad dffg va.

A vm a fd, v av

mgd a a agly mpa f

xal da ad fdaal lgal

advam.10 uv av a y

f a ala ad lgy ad av

pdd akg va a pawd

mlll-dlla d aa a

lgy ad i.

Y v w may mpllg xampl f val

a, gap w vy a ad

dy ma wd. W mpad w lg

ad f al pa r&D, gagg falyad a mmala f

da a faly dvlpm. A a l, a

da f apal, kwldg, ad pp f appld

a fqly pv dlay va

fm ag mak.

Dg la qa f 20 y,

vy-gad lgy f g

gg g lgy ff

f a ad va. i 1976, uvy f

calfa sa Fa (ucsF) Pf h

by ad v-apal r swa

fdd G, wld f lgy

mpay. by ad swa a mmd

$500 a a a wld am fd

mmal appla f ma DnA

lgy a by ad dvlpd w safd

g D. saly c 3 ya al.

by 1977, G pd pd f

f ma p mafad aa,

a v f dd f Ag f

blgy. o ya la, laa

a ucsF, by ld ma l g

g ma DnA lgy, ag

fda f a lmd pply f l.

t glal lgy dy a

m a $100 ll p ya . i

2009, G am a wlly wdday f sw pamaal ad

dag mpay, r, fllwg a $47

ll aq f 44 p f G

a alady wd y r a m.

G: uvy raspaw $100 bll idy 11,12

-Cost Saving

Health

Technologies

Healthc

are

IT

LifeSc

iences

Te

lecom

Low-PowerSensors

Mic

roel ectronic

s

CloudComputing

Wire

lessNe

twork

s

Figure 1. New Breed of Health Technology

Source: Booz Allen Hamilton


8/25


3the chALLenGe oF coMMerciALizinGeArLY-stAGe heALth technoLoGies

Dffcults f CmmrcalzatnW ampg mmal a lgy,

a fa allg dg a

f v, pp mam a may

may x a pala , ad k f fal dg aly ag

f dvlpm. Wl a a jy

q, f pl mpdma apal,

pal lma f adal lgy af,

d f pal kll, ad dffly

f avgag mplx f ala

maka mm adlk.

Lack of Risk Capital. cagg vm dyam

v la dad av ad a al gap

a apal w ga f a a

ad v apal. A d f pm,

gvm fdg ma lagly fd a,

appld a. o d, l agl ad

v apal avalal a v av

agly ald apal wad la-ag

mpa alady pd f mmal gw.

Daa fm Pwacp ad naal

V capal Aa w a al v

apal allad mpa fm d/a-p

la ag fll damaally w 1999 ad 2011,

fm $22.4 ll $6.6 ll, w al d/a-p vm dag y a fa f alm

10.13 Wl am vd 1999 laly fl

a pd f flad vm vlm ad xpa

aad w g f d m l,

f lav a f v apal y ag

ya a l valg. bw

1999 ad 2011, val f d/a-p vm

dad fm 5.5 p j 2 p f al

fdg, wl vm aly-ag mpa

gw fm 23 p aly 35 p f

al. (s Fg 2 fllwg pag.) t ag

lav a f apal a al ag f

vm dma a la mga wad l

k ad pv mpa, pv f aggga

am vd a gv ya.14

ra y c f V ra (cVr)

a uvy f nw hamp a w a

agl vg al a dad ad fd wad

lw k aa v la dad. cVr daa val

a al agl vm a dad y a d,

fm m a $30 ll 2001 appxmaly

$20 ll 2010. Alg agl v favd

aly-ag vm 2002 (47 p f alvm), d/a-p ag vm dld

j 31 p f agl apal 2010.15,16

Wl may a w agl ad d-ag

v fd appld a ad Poc pj,

d v ad agl apal gg a fw

ad fw a wllg gaml a ag.

F, a f al lgy va

pdad avg dama d,

may mply al xp lvl f

ypally qd f g-k, aly-ag vm.

Health technology innovations predicated on

achieving dramatic cost reductions may not be able to

provide the level of return that is typically expected in

exchange for high-risk, early-stage investments.


9/25

7

Potential Limitations of Traditional Technology Transfer.

i 1980, paag f bay-Dl A ald

v a wp f llal ppy

dvlpd d fdally fdd a ad

pakd f vy lgy af

ff (tto). Adg Aa f

uvy tlgy Maag, bay-Dl a fld

gfa gw mmala f vyv, ldg fma f m a 5,000

w mpa.17

ov m, wv, tto av ggld

ma pa f vy-ad va,

ad lma f adal lgy

af ym av m a pal a

mmala. i p

dfdg ad mm ag l f

adal lgy af, may v a

wkg mak lgy af p

fa ad m fdly. A gwg m

f a al pag p a

a tto w pgam dly fd ad

a mpa fdd vy a.

Mindset of Academic Researchers. i a w

fdg ad lgy af lma a

vm, aly-ag mmala ll q

addal kwldg ad kll a vy

a fqly d p. Aadm

av ally pad a vm w

pf a ky mva. iad, pla,

p g, ad da f d av

ppal wad f ff. hwv,

agly d vy lgy af

p, a wll a a d mv a

yd laay f pl ad pal

f, av ld may a p pa

ad llal ppy g f

mmala.

ev , a f fa malgm

w aadm ad v

(.g., pla, ), ad xp

ay ffly mv p wad

mmala. cvg a a pd

p ypally q a mak-ady lgy,a val mdl, pf f mak d, ad

-d maagm kll. Adg

rl oa, PD, xv d f v Lg

c, M aadm a av

mg p, ad fw a flly

mmal v w gda,

llaa, ad a ym f pp.

Complexity of the Healthcare Market. hala a

mplx ad gly glad dy a j

a pawk f fdal, a, ad lal law ad

gla. A gly fagmd dlvy ym

ad d paym mam a f ld

a a pa al ad al, makg

dffl aa vm apal. byd fdg,

a m al apa ldad

fl mak w g lvl f pay ad

pvd a, a wll a k-adv

glay ag ad mp fm

d mp pal .

Addg mplxy f mak

aal a f mdl ala dy. Wl f-f-v

mm ma dma fm f

paym, a wav f dmda ad k-fg

mgag paym agly wad m-

ad mdl ad aaly f al . t

ag p pp f al lgy

va, a al a mvg ag. t day f

1999 2005 2011

Seed/Start-Up

Early

5.5%2.7% 2.0%

23.1%

16.8%

34.5%

Figure 2. Change in Investment Stage as Share of TotalVenture Capital

Source: Booz Allen Hamilton analysis of data from PricewaterhouseCoopers

and the National Venture Capital Association


10/25


ldg y mdl ad a cPt d a

md, ad tma Ll, a v pd a

b All haml. ra ad p

dvlpg w al lg wll agly

d dma m ad val a

vm f k-ad paym.

Apprachs t Brdgng th Gapsakld a ampg dg gap

w vy a ad dy g

a vay f appa, ldg mpa vg,

p va pap, va allg,

ad vy gap fdg pgam. ea f

ff pal val vy a, ad all

may v a l f alag mmala

f -avg al lg.

Impact Investing. impa vm gally

a d- qy-ad vm mad y

fda a a dgd av a yp

al f al mpa a y ld av

g gamakg al.18 impa vg

al fda dply addal apal

ad gly pf pgamma ad vm

gal, w dpg m ad

agy f gaa. Fda may v

dly mpa ga xp dly

g alav vl, a mmm

fd fd pfl a v m-algd

ad pp.19

impa v aly ap alav

l dmadg m a a q

ppy pp mmala f aly-

ag al lg. Gv ff m

pgam algm, fda a vlk

aymm k pfl ad ap lgy val

pp a g d avg a

avdg a m ly pd dwamad

d al f ala. tadal

v ally f g- ad g-

advam pp lag vm w

pal f gfa pf, ad Maga Law,

MPP, d f calfa halca Fda

iva f udvd pgam.

Fda a play a mpa l alg

lw-, g-qaly a y fdg -avg

al lg.

Open Innovation Partnerships. t m p

va gad a aly a dad ag

w hy cg w a a w mdl f

va w mpa mmal

al ad xal va wl dg

alav paway f w da yd . i vlvg paadgm f p

va, adal r&D ml afmd

a m lly pld a fd

fdg, ga, ad mmala

f va. t m flxl mdl al

mpa mak ag d a w y

gag w xal pa ad wa l play

p f va.20 (s Fg 3.)

Without financial support for low-cost health

care innovation, the research we do at the Institute

and the work other agencies, institutions, and

entrepreneurs are undertaking will have a tougher

path toward becoming a reality and actually

lowering health care costs for the public. Gary West, chairman and founder of

West Wireless Health Institute

RESEAR H DE EL PMENT

Boundary

of the Firm

Research

Projects

Current

Market

Open Innovation Model

New

Market

Funding Generating Commercializing

Op n Innovation Mod l

Figure 3. Open Innovation Model

Henry Chesbrough, Open Innovation: The New Imperative for Creating and

Profiting from Technology, 2003


11/25

9

t p va paadgm p a g

val pp f al dy ad

pvd la f f aly-ag lgy

mmala. i ya, gaa

a Pf, GlaxsmKl, ad el Llly av

d p va pap a a way

lvag apal, fa, xp, ad

d apal ala mmala

f w ap.21 A a wad m-

dv paym mdl ad pald md

ala, ga llaa wll qd

amg pamaal, mdal dv, ad lgy

fm aa a mpa dag

dag d l mdfy f a

ap agad ga f gm ad

l al d daa.

Innovation Prizes and Challenges. i 2009, MKy

pd a f awad ad p aad damaally v pa dad.22

Awad av vlvd fm a l pmaly d f

gg avm a ym dgd

pd va aa a pa,

vm, ad ad gg. ov

pa 5 ya, al val f allg-ad

va fdg a ad gfaly, w

lag p pg al mad val f

mak f p ad allg w $1 ll

ad $2 ll.23

W gwg mak, ala a aad

a agly lag ad dv pl f allg-

ad va p. cpa- ad fda-

pd allg ala ly ag

fm mall p f vav al it appla

Ge $100 mll allg fd

alag d ad pald am

f a a.24

t fdal gvm al a mmd

gfa fdg wad p ad allg

g av a Mdal ivaP A f 2007, w ald a pl f $80

ll f dvlpm f vl ap. M

ff ld gy ad al va

allg, a wll a alm f a l

lag f gvm p.25, 26

t allg-ad appa ff mplmay

val f mlpl akld, ldg a,

mpa, fda, ad gvm. P

l allg a k va

lv a pf, wll-dfd plma

paway f a ffly g

pd mak, wl a am m

gfaly dg k f vm f

mpa fdg gaa. o yp f

allg, w gal a mak mla

mmy ldg, a dly pp aly-

ag dvlpm ad ala mmala

y lpg df mak famwk pd

paway ad y ag ym f pp ad

apal ad a.

University Gap Funding Programs. A gap fd

gally dfd a m maagd

ally xally a dg fdg gap w fdal fdg f

a ad f my fm d v.27

uv pag gaa av

dvlpd gap fdg pgam agm

adal lgy af p ad

a ad ala mmala.

Pgam vay wdly , , appa,

ad mmala p, a

gally gmd f pmay fd yp:

(1) alaal a, (2) Poc, (3)

fma, ad (4) gw. Fdg ypally

dd fm f ga vm a

ag fm a ll a $20,000 p $1 mll. 28

A 2011 vy f gap fd vald a m f

f, ldg g a f mmala,

mpvd g aly-ag apal,

ad gaaal . 29 (s Fg 4

fllwg pag.) i may a, a al ap

f gap fd val pp lva

f a ym a pp a ad

p y lpg m add pfgal ad qm a a ag

mmala p.


12/25


Government

Funded

University

Research

Advanced

Research

Projects

Agency

SBIR, STTR andInnovation Funds

Venture and Angel CapitalIncubators and

Crowdfunding

University Gap Funding

R&D Grant Funds $10Ks $100Ks $Millions

Private

Public

Universities

Basic

Research

Translational

Research

Proof of

Concept

Business

Formation

Expand and

ScaleIPO/M&A

SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer

Figure 4. Gap Funding Within the Landscape of Early-Stage Funding

Source: Adapted from Jacob Johnson, Mind the Gap: The University Gap Funding Report," innovosource, LLC, 2012


13/25

11

4htAP AnDthe ProoF-oF-concePt strAteGY

htAP a xampl f a gap fdg pgam a

lvag mpa vm fm fd f

av. i wa ad y Wllam J. v

Lg c f epm ad tlgy

Advam a uc sa Dg, pap

w calfa halca Fda, r

Wd J Fda, ad b All haml.

htAP a mpv pgam ala

mmala f vy a al

lg w pal f dg ala

ad xpadg a f dvd.

i f Poc ag f dvlpm, wl

g a gal lgy ala mdl

dfy vl, -avg al lg.

Th Wllam J. vn Lbg Cntrt v Lg c ff pgam ad v faly, a, ad d d

mmala f v lg fm

a. A f agy

mmala ml kw a Poc.

t Poc p dgd dm

mak faly f a v y dfg al

pfma aga mak d, dlvg

g-qaly adda w dd f mmal

. A Poc ag, a ma f d

fdg f pyp dvlpm ad a d

mmala pla gfaly a

val f lgy, makg m aav

v ad p.

i 2010, u.s. Amy tlmd ad Advad

tlgy ra c (tAtrc) ad Qalmm

i. pvdd v Lg c w ga fdg

adap Poc p a pa f a gal wl

al lgy ala pgam. t av

g dfy ad ala mmala

f vy ad a lg wl al a ld add mdal d f

mlay pl ad faml.

Wllam J. v Lg c f epm ad tlgyAdvam a uvy f calfa sa Dg

t v Lg c wa fdd 2001 ala mmala f uc sa Dgva makpla, f ad fala xag f da w uvy ad

dy, ad ppa d f pal wkpla. s p, a

vlvd w m a 300 pj, advd m a 200 faly mm ad gada d,

awadd $4.6 mll p-d ga 82 pj, ad ppd a ad gw f 32 a-p

mpa. cllvly, mpa av ad m a 200 j ad av vd m a

$100 mll fllw-p pva apal da.


14/25

12

A Unqu Prgramug wl al lgy ala

av a a mdl, v Lg ad htAP p

a a q pgam a wld

maa a gal f, y ad ladap

f pal appla y mvg xpl

qm a al lg wl. i

add, htAP amd dffa lf fm

lgy ala y qalfyg appla

ad aly d , a alyg ly v pf pal.

i htAP p, appla w f qd

m a am f (soi), ldg a

vvw f lgy ad ppd appla.

soi gdd m f a al pal f

dpd xp jdg ad falad al

g f appla ad lgly, ag f

dvlpm, ad pgam f. Fllwg a day

g ad lv va m a fll

ppal, a fal d f 12 papa wa vd mp f f f awad f p $100,000,

alg w a ya f mg fm a v

Lg adv.

Application Results. A f pgam, v

Lg dad a w v

ad a s calfa

g pal appla. htAP vd

64 soi p fm 11 a

g. soi fm uc sa Dg, uvy

f calfa a iv (uc iv), ucLA, ad

uvy f s calfa (usc) pd

alm 90 p f pd. t

mag 10 p gad fm pal,

a , ad a fda. A majy

f m w ld y m faly

mm fm l f gg

md, w appxmaly f appla

mg fm mldplay am pg

dpl.

Appla ppd pj a fv ag

f al lgy pag a ag f lgyk. t ldd ca Dlvy effy ad

om, baval iv, Dag

ad Mg Dv, sgal ad tap

Dv, ad tap Ag. t lag a

f appla (36 p) ppd pj f

Dag ad Mg Dv, wl tap

Ag w ppd ly 4 p f soi.

Appxmaly -d f all appla lvd

Goals of HTAP

Identify early-stage, university-based

technologies with the potential to:

Directlyorindirectlyreducethecostof

ala dlvy;

Drivethedeliveryofaservicetoalower-costg;

Useskilledprofessionalstimemoreefficiently

( al l-ad dvdal)

Apply cost-saving health technologies for:

Chronicdiseasemanagementathome;

Telehealthservices;and

Diagnostictestsandprocedures

Diagnostic andMonitoring Devices

Surgical andTherapeutic Devices

Care Deliveryfciency and Outcomes

BehavioralInterventions

TherapeuticAgents

23

18

15

6

2

Figure 5. Number of SOIs by Technology Category

Source: von Liebig Center Analysis


15/25


lgy wld dly lw f dlvg

ala, wl w-d ggd

pd wld mpv pa a, mpv

qaly f a f a pala g, .30

M a 20 soi ppd dag ad

mg lg, w may aly

da d w am m ffvad l xpv. Dv f m mg

a al d y falag daa

ll ad pg pvd pal wag

f m pd f ll. bf a

ld a da fqy f pala ad

dd a f adm.

oly x soi ppd lg f aval

v. t m f m wa aly

lw gv gwg lvl f a pv

ad wll amg al pla, mply,

ad pvd w d a ala

. oy ad lfyl-lad k fa

gfaly a dd f dvlpg ly

d a da, yp,

ad a da. tf, agg m

av al pvg f

d mpvg gg maagm f

da d .

i la wy fw appla agd

aval v. o a may a

f wll w al dyad mgg f av ag a

lavly dvlpm. ra may

al am a p w a fd

av ag wll lvag xg lg,

a a lk f pp mmal

w dv. Wav a, pj

a Ml Madm ( p)a ml

l f a-m wg mala ppd y

D. Mal L a uvy f calfa a iv

dma pal pw f -avg al

lg a f agg av.

Screening Process. All soi w ally d

adg a lgly qm,

pv pgam gal, ad w

pj wa yd Poc ag. (s Fg 6

fllwg pag.) t 28 soi a pad al

g w valad y a xpadd pal f

vw ad a mpa f lav mdal

mpa ad lgal vly.

t 12 fal w a pad w a v Lg

adv ppa f -p pa a

pal f dpd xp jdg a v Lgfal sa Dg. Jdg d a wgd

g ym ad f akg l f

av w, ldg D. oa, v p

$100,000 adva lg wad

mmala. t awad w jd

a pd f d dlg add ay p

q fm jdg ad vfy pa flg

a. t w wkd w v Lg

adv a a lgy dvlpm pla,

dg, ad ga paym ml. t ad

ya-lg mg pgam.

Photo 2: Mobile Mandometer

Credit: Jenny Nolstam, The Mando Group


16/25

14

Initial Screen

of All SOIs

Secondary

Review of SOIs

In-Person

Presentations

Winners

Selected

12-Month

Program Begins

64 28 12 4

SOIs screened for:

Eligibility

Fit with

impact/interest

areas

Stage of

development

Expanded panel

reviews SOIs for:

Relative medical

importance

Technological

novelty

Finalists present to

a panel of expert

judges

Due diligence on

tentative winners:

Open questions

Patent ling

status

Awardees work with

a von Liebig Center

advisor to develop their

plan, budget, and

payment milestones

Screening &

Selection

Researchers begin

by submitting a

statement of interest(SOI), including an

overview of their

technology and

proposed application

vLC64 28 12 vLC

Screenin &

R s r hers begin

by submit ing a

st t m nt interest(SOI), in uding n

verview of their

t hnology n

pr p s applic ti n

Figure 6. HTAP Screening and Selection Process

Source: Booz Allen Hamilton and von Liebig Center


17/25

htAP Winners

Awad w mad f am f fm uc iv, uc sa Dg, ad ucLA, pg w

aly-ag mpa ad w am w p-pa ag a. t wg pj d

f w p-f-a dag l, a ld-ad pa am plag ym, ad a map-

ad wg-l maagm l. b dag l w plafm-ad va w applaf mlpl da, wl am plag ad aval v lg agd a

ad y, pvly. All w pad a la w f ky al f -avg al

lgml, lw-pw , wl wk, ad ld mpg.

Microscopy on a Cell-phone as a Diagnostic Tool (LUCAS)Aydogan Ozcan, PhD, University of California, Los Angeles

STAGe

CATeGoRy

CoNDiTioN

Company Formed

Diagnostic and Monitoring Devices

Multiple

iMPACT

eNABLeRS

Cost, Quality, Access

Microelectronics, Sensors, Wireless

t ucLA gp pd a l-f, -p magg mdaly md LucAs, w al val

ll-p vd mp ad dag l, pvdg a mpa l va

al md d. t f appla f LucAs cmpl bld c (cbc).

Mdy ad maly a dppally g ld fm -p g ad dfad

ppla, palaly lvg al y aa f ud sa. Pvy, p a

ala, p , ad lw lvl f paal da a pdpg fa. o maj plm

affg yg ld dfad ppla vlaly f fllwd y ama ad

p . A al laay f ad dag ad maagm f d a cbc,

f m wdly dd laay md.

W a avalaly f cbc l, pya, pya aa, pa wll

a p mak a dag ad p g dg dg a al pa a a

a ak pla paally ayw, w l la a v (a mpla

p mm). t plafm a al d, g lmd, gd fal mdal

v. F, y dg - a a dg ld pm d laa,

pvd a ap gfa addal val f mlv . t f pala

mpa f may gaa a a ally dfdd ad dpd gvm

plap ag.



18/25

Low-Cost Semiconductor Test Strips for Accurate In Vitro DiagnosticsChi On Chui, PhD, University of California, Los Angeles

STAGe

CATeGoRy

CoNDiTioN

Pre-incorporation

Diagnostic and Monitoring Devices

Multiple

iMPACT

eNABLeRS

Cost, Access

Microelectronics, Sensors

t pj k xpl a lw-, a-gd lgy f apd, p-f a dag

(.g., emgy Dpam, iv ca u, amla, pya ff, .). Poc daa a

ad ad dma 10 m ga vy, w l avalal m. t f

dag ag f lgy a ada jy mak a appa aly ld ampl,

a vy lw a mmdaly fllwg a aak. t plafm lgy wll pakagd

a mpl adld ad fad w a dpal p ad wll lmaly appld

da dag p-f-a a w a f , fa l, ad lw a al f

adp, pally aa w ala a adqa.

GPU and Cloud-Based Next-Generation Cancer RadiotherapyTreatment PlanningSteve Jiang, PhD, and Yuanyuan Zhou, PhD, University of California, San Diego

STAGe

CATeGoRy

CoNDiTioN

Pre-incorporation

Efficiency and Outcomes

Cancer

iMPACT

eNABLeRS

Cost, Quality

Cloud Computing, Wireless

i ud sa, a w-d f a pa a ad w adapy dlv a lal d

f ada m kll a ll wl pag dg aly ga ad mal .

t am mplx ad gly pa pf. tam plag dd y pla g a

ddad mp ad fwa ym alld a tam Plag sym. A fd am pla

d aflly pd ad appvd y adg pya f a d a

pa. t am plag ym a xpv, ad p f plag ff.

i f ak 1 2 wk f a lally apal am pla avd ad appvd y

pya. Mv, am daa d dvdal ad va fma, ly

maa daa ad dffl a daa amg .

i pj, vga wll dvlp a x-ga, w-ad am plag ym

mplyg gap pg (GPu) fwa ad ld mpg. tam plag wll

pfmd ld, ad pal wll mply pay a f f pg a pla. Mv, w ym, GPu-ad mpa g d pd p mpaally v ak

plag p, a a pmal am pla a ampld vy apdly ad g

gfaly l pya m. cmg f f ld mpg ad GPu g-pd pg,

w ym wll d f am plag, pfal m, ag

am daa ag, ad mpv la f adapy dv.

16


19/25

Mobile Mandometer for At-Home Weight NormalizationMichael Leon, PhD, University of California, Irvine

STAGe

CATeGoRy

CoNDiTioN

Company Formed

Behavior Modification

Obesity

iMPACT

eNABLeRS

Cost, Access

Sensors, Wireless

t Mad Gp a dvlpd wa appa a ffv am f y, fa a ly

dmad apy a lavly xpv l-ad pgam w pa a ad

mal fd ak pa g fdak a ag av dg ad w

mal. Pa a mal w a Madm(mad ma i a La), w f a

al a d a d pla a d fma a ag av a mall m.

t ag av f a mal-wg p mg am mal al w m,

allwg pa mdl ag av mal pa. s ag allw m la

mal flg a gd aly wg dvdal ma mal.

t mak pgam avalal may m ppl, gp pp d f am

y mvg f l. ty wll pw f P ad Add pag ym dvlp: 1) a ml malm fdak dv a wll lp pa la g ay dg

a mal, 2) a ml dv a ppl a ly w y a gy, ad 3) a ml val

ap, w a avaa aw m a 4,500 q a av a pv

a w pa, pvdg addal paal pp dd f a ffv wg-l

pgam d f l. t ga wll d dvlp a w-ga al f

malm fdak dv a wll m l xpv pd, a galy mpvd paly,

ad a mma wlly w map.



20/25

18

Nxt Stps fr HTAP Wnnrst awad a w wkg wad mplg

dvlpm ml a a am ald

w gda fm v Lg adv. t mg

ad yp f a w ga wad v Lg adv vay adg

pf ma ad pj ag f

dvlpm. MbA d fllw fm uc sa

Dg' rady sl f Maagm av

agd f pj w pp

mmala ff g mak a

ad pla dvlpm. hwv, d

gal am: dma Poc ad df a

mmala paway.

ov f ya, awad wll d

a df m d ad mak

ppy, a wll a a mpv

ladap. D. c ad Jag f wm a

plly mmd a mmala pawll

al wk w v Lg adv vw

mdl a appa lva f lgy ad

g wgg p f ag a mpay

kg a l. cg a mmala

paway a a mplx ad dffl d.

cqly, v Lg wll wk w D. c ad

Jag d ad q a:

Lkld f g pa p

W v a plafm lgy

a mal mpvm

capal qm

Mak dyam

iv awa pal

Pal ag a ap ad

lgy

5LooKinG AheAD

Photo 3: Disposable Semiconductor Test Strip Prototype

Photo 4: GPU and Cloud-Based Cancer RadiotherapyTreatment Planning System

Credit: Chi on Chui, UCLA Engineering

Credit: Steve Jiang, UC San Diego Moores Cancer Center


21/25

19

if a mm f c Jag am wa l

lgy fm pv vy

ad k apal a a mpay, v Lg wll

wk w pj am fy f

appla ag, fm f mak

ppy, ad vala va gap-fdg

pp. Fdg p mg ld applyg

f a small b iva ra (sbir)

a appag aly-ag v g

da w gp a gal agl

vm wk. v Lg al wll pvd

gda w ppa f fmal pa

v.

D. L ad oa, w av alady fmd

mpa ad pj ad d pva

d apal, wll p a dff pa fwad

ad ag f dvlpm ad mmal

advam da.

D. L ad am wll wkg w gda

fm v Lg mpl fwa dvlpm

ad a al pyp f Ml Madm,

w jv f g ady f pd a

d f htAP pgam pd. if am

mak ff pg, v Lg wll al

pvd gda makg agy ad mak

d addal v.

D. oa v, LucAs, wll fllw a dff

pa. Fd fm htAP awad wll d y oa ra Gp a ucLA dvlp

pf appla f LucAs f p-f-a cbc

g ld gp htAP ppal. A

am m, D. oa w mpay, hlm, LLc,

wll pva vm apal f dvlp

LucAs plafm f addal appla f

lgy. v Lg wll wk w D. oa

ad ceo f hlm d mak ad

pa a qd f-

ad makg pla f appla f LucAs f

cbc g.

iv ad aly pg f awad,

a D. oa ad L, gly agg.

t a aly aa pva apal

dma ll a pl f v wllg

ak g-k vm -avg al

lg, v a aly-ag f dvlpm.

W add f gda fm v Lg ad

ga fdg fm htAP p, LucAs ad

Ml Madmav a gd a f vvg

mmala p ad dlvg f

pa a a lw .

earl insghts and CnsdratnsA htAP awad fg aad, wll

lp llma fll mpa f htAP v m.

Alg htAP wg av a ll a

aly ag, a plmay g a a ff

gda f gvm, vy, ad mmal

akld w a gal f alag

mmala f -avg al lg.

Changing Industry Dynamics. Stakeholders should

increase awareness among researchers about the

implications of industry convergence and changing

payment models.

A a vga lg w

pal d ala , mpa

a awa a w vg a

ala, lf , ad lmma

d a aff dvlpm qm

ad glay p. F xampl, all

f htAP awad dly pad f

wl lg v. A a l,

y wll d apa ml y ad daa

am adad add us Fd

ad Dg Adma appval p f a

ypal mdal dv.


22/25


i qally mpa f dvlp f aly-ag

al lg dad agg paym

ad mdl. A dy f

wad m gad ad aal mdl

f a dlvy, w al lg wll d

ga w a ag f al fma

lg, ldg l al d.

ra wll al d apa

mpa f aval daa gad d f

adal a g a lp al a m

l vw f pa.

Program Specialization.Funders and universities

should consider the value of programs that target

specific areas of need and opportunity.

htAP lla w a m gald lgy

ala pgam mdl a appld

aa f -avg al lg. Aaly

f htAP m gg a a

ppy f pgam w a v ga dg

f pala. by alg m agd

pgam jv, fd ad pgam fala

a mpv dd f dfyg akg

va aa f al d.

Regional Program Models.Universities and funders

of acceleration programs should consider the value

of regional models and how unique requirements will

affect program development.

Ml-vy mdl a ff gfa val

y dg f dvlpg ala

pgam. ty al f ym f pp

f a ad p a xd

yd a ad f ay gl

vy. hwv, gal mdl may al

a d f w pl ad p.

F htAP, v Lg ald pal agm

w papag v add

qm f a ml-vy pgam, ldg

g ga paym a ad

dvlpm ml.

National Referral Network.Stakeholders should

consider creating an actively managed national referral

network that connects new technologies to funding,

investment, and commercial opportunity.

t f htAP w w al mg

mpllg a da. bad pgam,

a htAP, ff f f aag a dv f da a a lag ppla f a.

i m a, wv, al avalal fdg fall

f wa ay pp all wy

m. sm v may al m

mak a pala pgam, y ld pm f

valad aga dff a.

All akld ld f fm a lag-al

fal wk f aly-ag al lg.

A avly maagd aal wk a gag

v, v, ad mmal lad a

pa wld a addal ppy f

pmg a fd fdg ad mmal

paway yd d f a gl pgam.

Commercial Insight. Industry should work more closely

with universities and funders to establish stronger

connectivity between academic research and defined

commercial needs.

o f m mpa akaway fm htAP

fa pg d f g

w mmal lad ad vy a.

W dv laay, m

a a pdg a pf mak

ppy dg qm f

mmal . t l a g paly

f malgm ad ffy a aly-ag

lg amp fd way mak ad

dy k va. cmmal paway

may v l la a f -avg

al lg. W ga d ad

dfd mmal pp, p wll

m ld lp a dvlp

lg, ad v wll av dd

f .


23/25

21

enDnotes

1. The Scientist, tp t iva 2011,

Jaay 2012. Avalal a: p://-.

m/2012/01/01/p--va-2011/

2. Ka Famly Fda, hal ca c:

A Pm, May 2012. Avalal a:p://www.kff.g/a/7670.fm

3. c f Mda & Mdad sv, off

f Aay, "naal hal expd

Pj 2010-2020." Avalal a:

p://www.m.gv/ra-sa-Daa-

ad-sym/sa-td-ad-rp/

naalhalexpdDaa/Dwlad/pj2010.pdf

4. t cmmwal Fd, Wy n

b? rl fm naal sad

u.s. hal sym Pfma, 2011,o 2011. Avalal a:

p://www.mmwalfd.g/Pla/

Fd-rp/2011/o/Wy-n--b-2011.apx

5. t bkg i, eglg c f

hal ca rfm, bdg v:

ffv p add lg-m al a

pdg gw, spm 2009. Avalal

a: p://www.kg.d/a/

p/2009/09/01-

6. u.s. cgal bdg off, tlgal

cag ad Gw f hal ca spdg,

Jaay 2008. Avalal a:

p://www..gv/pla/41665

7. b M.b., Ja s.h., ad blmal D., hal

ifma tlgy: Layg t ifa

f naal hal rfm, hal Affa, J

2010, 29(6): 12141219.

8. c c., Gma, J., ad hwag, J.,The Innovators Prescription, MGaw-hll, 2008

9. Al, W.K., Dvg iva i Lag

cpa i: callg Fad y Lag

cpa, The MIT Entrepreneurship Review,

Apl 2010. Avalal a: p://m.m.d/

al/dvg-va-lag-pa--

allg-fad-lag-pa

10. cg h., Vaavk W., ad Jl W,

Open Innovation: Researching a New Paradigm,

oxfd uvy P, 2006

11. Pbs. og, Who Made America, Innovators, Herbert

Boyer. Avalal a: p://www.p.g/wg/

ymadama/wmad/y_.ml

12. G, Corporate Chronology. Avalal a:

p://www.g.m/g/a/pa/

y/ml.ml

13. Pwacp LLP ad naal

V capal Aa, Myt

rp, qaly al d daa fm19992011. Avalal a:

p://www.pwmy.m/MtPl//

av.jp?pag=al
http://the-scientist.com/2012/01/01/top-ten-innovations-2011/http://the-scientist.com/2012/01/01/top-ten-innovations-2011/http://www.kff.org/insurance/7670.cfmhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/proj2010.pdfhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/proj2010.pdfhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/proj2010.pdfhttp://www.commonwealthfund.org/Publications/Fund-Reports/2011/Oct/Why-Not-the-Best-2011.aspxhttp://www.commonwealthfund.org/Publications/Fund-Reports/2011/Oct/Why-Not-the-Best-2011.aspxhttp://www.brookings.edu/research/reports/2009/09/01-btchttp://www.brookings.edu/research/reports/2009/09/01-btchttp://www.cbo.gov/publication/41665http://miter.mit.edu/article/driving-innovation-large-corporations-i-challenges-faced-large-corporationshttp://miter.mit.edu/article/driving-innovation-large-corporations-i-challenges-faced-large-corporationshttp://miter.mit.edu/article/driving-innovation-large-corporations-i-challenges-faced-large-corporationshttp://www.pbs.org/wgbh/theymadeamerica/whomade/boyer_hi.htmlhttp://www.pbs.org/wgbh/theymadeamerica/whomade/boyer_hi.htmlhttp://www.gene.com/gene/about/corporate/history/timeline.htmlhttp://www.gene.com/gene/about/corporate/history/timeline.htmlhttps://www.pwcmoneytree.com/MTPublic/ns/nav.jsp?page=historicalhttps://www.pwcmoneytree.com/MTPublic/ns/nav.jsp?page=historicalhttps://www.pwcmoneytree.com/MTPublic/ns/nav.jsp?page=historicalhttps://www.pwcmoneytree.com/MTPublic/ns/nav.jsp?page=historicalhttp://www.gene.com/gene/about/corporate/history/timeline.htmlhttp://www.gene.com/gene/about/corporate/history/timeline.htmlhttp://www.pbs.org/wgbh/theymadeamerica/whomade/boyer_hi.htmlhttp://www.pbs.org/wgbh/theymadeamerica/whomade/boyer_hi.htmlhttp://miter.mit.edu/article/driving-innovation-large-corporations-i-challenges-faced-large-corporationshttp://miter.mit.edu/article/driving-innovation-large-corporations-i-challenges-faced-large-corporationshttp://miter.mit.edu/article/driving-innovation-large-corporations-i-challenges-faced-large-corporationshttp://www.cbo.gov/publication/41665http://www.brookings.edu/research/reports/2009/09/01-btchttp://www.brookings.edu/research/reports/2009/09/01-btchttp://www.commonwealthfund.org/Publications/Fund-Reports/2011/Oct/Why-Not-the-Best-2011.aspxhttp://www.commonwealthfund.org/Publications/Fund-Reports/2011/Oct/Why-Not-the-Best-2011.aspxhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/proj2010.pdfhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/proj2010.pdfhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/proj2010.pdfhttp://www.kff.org/insurance/7670.cfmhttp://the-scientist.com/2012/01/01/top-ten-innovations-2011/http://the-scientist.com/2012/01/01/top-ten-innovations-2011/


24/25

22

14. b All haml aaly

15. c f V ra, t Agl iv

Mak 2002: ivm Avy ad Gw

Pp, J 2003. Avalal a: p://w.

.d/fl/c_f_V_ra_

P_rla_J_2003_-_t_Agl_iv_

Mak__2002.pdf

16. c f V ra, t Agl iv

Mak 2010: A Mak rd, Apl

2011. Avalal a: p://w..d//

dfal/fl/2010_aaly_p.pdf

17. Aa f uvy tlgy Maag,

ty Ya Af Paag, bay-Dl A Dv

emy, P Pl hal, May 2010.

Avalal a: p://www.ww.m/al/

y-ya-af-paag-ay-dl-a-dv--

my-p-pl-al

18. Ga Mak hal, Gd impa

ivg, May 2011. Avalal a: www.g.g/

fl/d/Gih_Gd__impa_ivg_

FinAL_May_2011.pdf

19. id.

20. cg, h.W, t ea f op iva,

Sloan Management Review, 2003, 44, 3 (spg):

3541

21. ra, M, Pf a aadmaaga, Nature Biotechnology, 2011, 29 (1), 34.

Avalal a: p://www.a.m//jal/

v29/1/fll/0111-3.ml

22. MKy & c, Ad w capg

pm f plap p, Jly

2009. Avalal a: p://www.mky.m/

App_Mda/rp/sso/Ad__w_.pdf

23. id.

24. Mlad, Mk, Ge p a a,

Healthcare IT News, nvm 3, 2011. Avalal

a: p://www.alaw.m/w/

g-p-a-a

25. ud sa cg, h. Mdal

iva P A f 2007. Avalal a:

p://www.gp.gv/fdy/pkg/biLLs-

1102210/pdf/biLLs-1102210.pdf

26. www.allg.gv

27. J, J., Mind the Gap: The Evolution of

Technology Commercialization, the Growing FundingGap, and What Research Institutions Are Doing About

It," off f b Dvlpm, uvy f

Ma, 2005. Avalal q.

28. J, J., Mind the Gap 2011: The University

Gap Funding Report, iv, nvm

2011. Avalal a: p://www.gapfdg.g/

addm/MtG11_ovvw.pdf

29. id.

30. v Lg c aaly f htAP appla.

i m a, l xama f

m dad a mpvm

qaly a may k -m a

.
http://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/sites/default/files/2010_analysis_report.pdfhttp://wsbe.unh.edu/sites/default/files/2010_analysis_report.pdfhttp://www.newswise.com/articles/thirty-years-after-passage-bayh-dole-act-drives-the-economy-protects-public-healthhttp://www.newswise.com/articles/thirty-years-after-passage-bayh-dole-act-drives-the-economy-protects-public-healthhttp://www.newswise.com/articles/thirty-years-after-passage-bayh-dole-act-drives-the-economy-protects-public-healthhttp://www.gih.org/files/usrdoc/GIH_Guide_to_Impact_Investing_FINAL_May_2011.pdfhttp://www.gih.org/files/usrdoc/GIH_Guide_to_Impact_Investing_FINAL_May_2011.pdfhttp://www.gih.org/files/usrdoc/GIH_Guide_to_Impact_Investing_FINAL_May_2011.pdfhttp://www.nature.com/nbt/journal/v29/n1/full/nbt0111-3.htmlhttp://www.nature.com/nbt/journal/v29/n1/full/nbt0111-3.htmlhttp://www.mckinsey.com/App_Media/Reports/SSO/And_the_winner_is.pdfhttp://www.mckinsey.com/App_Media/Reports/SSO/And_the_winner_is.pdfhttp://www.healthcareitnews.com/news/ge-puts-cancer-crosshairshttp://www.healthcareitnews.com/news/ge-puts-cancer-crosshairshttp://www.gpo.gov/fdsys/pkg/BILLS-110s2210is/pdf/BILLS-110s2210is.pdfhttp://www.gpo.gov/fdsys/pkg/BILLS-110s2210is/pdf/BILLS-110s2210is.pdfhttp://www.challenge.gov/http://www.gapfunding.org/shareddocuments/MTG11_Overview.pdfhttp://www.gapfunding.org/shareddocuments/MTG11_Overview.pdfhttp://www.challenge.gov/http://www.gpo.gov/fdsys/pkg/BILLS-110s2210is/pdf/BILLS-110s2210is.pdfhttp://www.gpo.gov/fdsys/pkg/BILLS-110s2210is/pdf/BILLS-110s2210is.pdfhttp://www.healthcareitnews.com/news/ge-puts-cancer-crosshairshttp://www.healthcareitnews.com/news/ge-puts-cancer-crosshairshttp://www.mckinsey.com/App_Media/Reports/SSO/And_the_winner_is.pdfhttp://www.mckinsey.com/App_Media/Reports/SSO/And_the_winner_is.pdfhttp://www.nature.com/nbt/journal/v29/n1/full/nbt0111-3.htmlhttp://www.nature.com/nbt/journal/v29/n1/full/nbt0111-3.htmlhttp://www.gih.org/files/usrdoc/GIH_Guide_to_Impact_Investing_FINAL_May_2011.pdfhttp://www.gih.org/files/usrdoc/GIH_Guide_to_Impact_Investing_FINAL_May_2011.pdfhttp://www.gih.org/files/usrdoc/GIH_Guide_to_Impact_Investing_FINAL_May_2011.pdfhttp://www.newswise.com/articles/thirty-years-after-passage-bayh-dole-act-drives-the-economy-protects-public-healthhttp://www.newswise.com/articles/thirty-years-after-passage-bayh-dole-act-drives-the-economy-protects-public-healthhttp://www.newswise.com/articles/thirty-years-after-passage-bayh-dole-act-drives-the-economy-protects-public-healthhttp://wsbe.unh.edu/sites/default/files/2010_analysis_report.pdfhttp://wsbe.unh.edu/sites/default/files/2010_analysis_report.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdfhttp://wsbe.unh.edu/files/Center_for_Venture_Research_Press_Release_June_2003_-_The_Angel_Investor_Market_in_2002.pdf


25/25

Documents

Accelerating Commercialization Cost Saving Health Technologies Report